Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Edward Cha

Showing results (11-20 of 27) with videos related to

Pageof 3
Sort By:
Current Oncology (Toronto, Ont.)|December 23, 2021
Phase Ib Study of Atezolizumab Plus Interferon-α with or without Bevacizumab in Patients with Metastatic Renal Cell Carcinoma and Other Solid TumorsChristian U Blank, Deborah J Wong, Thai H Ho, et al.
International Journal of Cancer|March 7, 2020
Phase 1 study of epacadostat in combination with atezolizumab for patients with previously treated advanced nonsmall cell lung cancerMatthew D Hellmann, Scott Gettinger, Laura Q M Chow, et al.
Oncoimmunology|May 4, 2016
GM-CSF and ipilimumab therapy in metastatic melanoma: Clinical outcomes and immunologic responsesSerena S Kwek, James Kahn, Samantha K Greaney, et al.
The Lancet. Oncology|December 25, 2025
Tiragolumab plus atezolizumab and chemotherapy as first-line treatment for patients with unresectable oesophageal squamous cell carcinoma (SKYSCRAPER-08): a randomised, double-blind, placebo-controlled, phase 3 trialChih-Hung Hsu, Zhihao Lu, Shegan Gao, et al.
Journal of Hepatology|January 24, 2026
Updated data from IMbrave050: Adjuvant atezolizumab plus bevacizumab for high-risk hepatocellular carcinomaAdam Yopp, Minshan Chen, Ann-Lii Cheng, et al.
JTO Clinical and Research Reports|July 25, 2022
Brief Report: Safety and Antitumor Activity of Alectinib Plus Atezolizumab From a Phase 1b Study in Advanced <i>ALK</i>-Positive NSCLCDong-Wan Kim, Shirish Gadgeel, Scott N Gettinger, et al.
Nature Medicine|June 8, 2019
Atezolizumab plus cobimetinib and vemurafenib in BRAF-mutated melanoma patientsRyan J Sullivan, Omid Hamid, Rene Gonzalez, et al.
The Oncologist|February 25, 2026
Atezolizumab and Motixafortide, Cobimetinib or Simlukafusp Alfa in Pretreated Advanced Pancreatic Cancer: Phase I/IIb MORPHEUS-PDAC Umbrella StudyGulam A Manji, Vincent Chung, Do-Youn Oh, et al.
The Lancet. Oncology|January 24, 2025
Tiragolumab in combination with atezolizumab and bevacizumab in patients with unresectable, locally advanced or metastatic hepatocellular carcinoma (MORPHEUS-Liver): a randomised, open-label, phase 1b-2, studyRichard S Finn, Baek-Yeol Ryoo, Chih-Hung Hsu, et al.
The Lancet. Oncology|December 25, 2025
First-line tiragolumab plus atezolizumab and chemotherapy in patients with previously untreated, locally advanced unresectable or metastatic oesophageal cancer (MORPHEUS-EC): a randomised, open-label, phase 1b/2 trialJong-Mu Sun, Yee Chao, Sung-Bae Kim, et al.
Pageof 3

Showing results (11-20 of 27) with videos related to

Sort By:
Pageof 3
Current Oncology (Toronto, Ont.)|December 23, 2021
Phase Ib Study of Atezolizumab Plus Interferon-α with or without Bevacizumab in Patients with Metastatic Renal Cell Carcinoma and Other Solid TumorsChristian U Blank, Deborah J Wong, Thai H Ho, et al.
International Journal of Cancer|March 7, 2020
Phase 1 study of epacadostat in combination with atezolizumab for patients with previously treated advanced nonsmall cell lung cancerMatthew D Hellmann, Scott Gettinger, Laura Q M Chow, et al.
Oncoimmunology|May 4, 2016
GM-CSF and ipilimumab therapy in metastatic melanoma: Clinical outcomes and immunologic responsesSerena S Kwek, James Kahn, Samantha K Greaney, et al.
The Lancet. Oncology|December 25, 2025
Tiragolumab plus atezolizumab and chemotherapy as first-line treatment for patients with unresectable oesophageal squamous cell carcinoma (SKYSCRAPER-08): a randomised, double-blind, placebo-controlled, phase 3 trialChih-Hung Hsu, Zhihao Lu, Shegan Gao, et al.
Journal of Hepatology|January 24, 2026
Updated data from IMbrave050: Adjuvant atezolizumab plus bevacizumab for high-risk hepatocellular carcinomaAdam Yopp, Minshan Chen, Ann-Lii Cheng, et al.
JTO Clinical and Research Reports|July 25, 2022
Brief Report: Safety and Antitumor Activity of Alectinib Plus Atezolizumab From a Phase 1b Study in Advanced <i>ALK</i>-Positive NSCLCDong-Wan Kim, Shirish Gadgeel, Scott N Gettinger, et al.
Nature Medicine|June 8, 2019
Atezolizumab plus cobimetinib and vemurafenib in BRAF-mutated melanoma patientsRyan J Sullivan, Omid Hamid, Rene Gonzalez, et al.
The Oncologist|February 25, 2026
Atezolizumab and Motixafortide, Cobimetinib or Simlukafusp Alfa in Pretreated Advanced Pancreatic Cancer: Phase I/IIb MORPHEUS-PDAC Umbrella StudyGulam A Manji, Vincent Chung, Do-Youn Oh, et al.
The Lancet. Oncology|January 24, 2025
Tiragolumab in combination with atezolizumab and bevacizumab in patients with unresectable, locally advanced or metastatic hepatocellular carcinoma (MORPHEUS-Liver): a randomised, open-label, phase 1b-2, studyRichard S Finn, Baek-Yeol Ryoo, Chih-Hung Hsu, et al.
The Lancet. Oncology|December 25, 2025
First-line tiragolumab plus atezolizumab and chemotherapy in patients with previously untreated, locally advanced unresectable or metastatic oesophageal cancer (MORPHEUS-EC): a randomised, open-label, phase 1b/2 trialJong-Mu Sun, Yee Chao, Sung-Bae Kim, et al.
Pageof 3